Intrexon and Merck Serono announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.
This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.
Utilizing Intrexon's cell engineering techniques and RheoSwitch platform, the collaboration aims to develop leading-edge products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy.
|Searching for more deal information? Current Partnering offers the following options:
The agreement provides Merck Serono exclusive access to Intrexon's proprietary and complementary suite of technologies to engineer T-cells with optimized and inducible gene expression, as recently strengthened by a license agreement with the University of Texas MD Anderson Cancer Center.
Intrexon will be responsible for all platform and product developments until IND filing.
Merck will nominate targets of interest for which CAR-T products will be developed.
Merck will also lead the IND filing and pre-IND interactions, clinical development and commercialization.
In addition, Intrexon has the opportunity to explore targets independently, granting Merck opt-in rights during clinical development.
Intrexon will receive an upfront payment of $115 million.
For the first two targets of interest selected by Merck Serono, Intrexon will receive research funding and is eligible to receive up to $826 million development, regulatory and commercial milestones, as well as tiered royalties on product sales.
In addition, Intrexon is also eligible to receive further payments upon achievement of certain technology development milestones.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies